Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs.
AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S207-13. Unique Identifier : AIDSLINE MED/95169483 Marmor M; Titus S; Wolfe H; Krasinski K; Maslansky R; Simberkoff M; Beatrice S; Nichols S; Des Jarlais DC; Department of Environmental Medicine, New York University School; of Medicine, NY 10010.
Abstract:
The likelihood that subjects in human immunodeficiency virus (HIV) vaccine efficacy trials will alter their behavioral risks for HIV infection over time must be considered in evaluating the feasibility of such trials and in estimating the necessary sample sizes to be enrolled. Potential subjects for future vaccine efficacy trials include injecting drug users (IDUs) and others who may be difficult to retain in studies and who may alter HIV-risk-related behaviors substantially over time. We have investigated behavior change, retention, and HIV seroconversion among 577 New York City resident IDUs and sexual partners of IDUs enlisted between July 1 and December 31, 1992. We attempted to see all subjects every 3 months for interviews, blood donation and HIV testing. We were able to retain 68% of subjects in the study through the third scheduled recall at 7.5-10.5 months after enlistment. HIV seroconversion through March 1, 1994, was 1.33/100 person-years at risk. There was a significant inverse relationship between HIV seroconversion and retention at the 9-month recall after adjusting for age, gender, and the amount of locator information provided by subjects at enlistment. Among subjects seen at each of the scheduled visits at 3, 6, and 9 months after enrollment, modest but statistically significant behavior changes that reduced risk were observed in self-reported drug injection frequency, heroin injection frequency, sexual contact with IDUs, and sharing of needles/syringes. The magnitude of these changes in risk, however, was small and may be transient. The behavior changes observed to date do not appear to be large enough to substantially alter calculations of sample sizes needed in future HIV vaccine efficacy trials.
Keywords: Adolescence Adult Aged AIDS Vaccines/*PHARMACOLOGY Clinical Trials/*METHODS/PSYCHOLOGY Cohort Studies Female Human HIV Seropositivity/*COMPLICATIONS/EPIDEMIOLOGY/PSYCHOLOGY Male Middle Age New York City Odds Ratio Patient Compliance Patient Selection Risk-Taking Sexual Partners/PSYCHOLOGY Substance Abuse, Intravenous/*COMPLICATIONS/*PSYCHOLOGY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Time Factors JOURNAL ARTICLE 950630
M9561133
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
